WBG
IDNA icon

Wharton Business Group’s iShares Genomics Immunology and Healthcare ETF IDNA Stock Holding History

Wharton Business Group’s Portfolio IDNA Stock Details IDNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.06M Sell
268,472
-1,515
-0.6% -$45.4K 0.3% 50
2026
Q1 		$7.84M Sell
269,987
-3,160
-1% -$91.7K 0.3% 50
2025
Q4 		$7.15M Sell
273,147
-12,630
-4% -$325K 0.27% 51
2025
Q3 		$6.75M Sell
285,777
-4,950
-2% -$109K 0.29% 49
2025
Q2 		$5.96M Buy
290,727
+5,255
+2% +$106K 0.25% 51
2025
Q1 		$5.85M Buy
285,472
+14,855
+5% +$332K 0.26% 50
2024
Q4 		$6.12M Sell
270,617
-282
-0.1% -$6.77K 0.28% 52
2024
Q3 		$6.67M Hold
270,899
– – 0.3% 52
2024
Q2 		$6.26M Buy
270,899
+1,345
+0.5% +$31.5K 0.32% 51
2024
Q1 		$6.49M Buy
269,554
+68,890
+34% +$1.61M 0.31% 49
2023
Q4 		$4.62M Sell
200,664
-82,700
-29% -$1.66M 0.23% 54
2023
Q3 		$5.77M Buy
283,364
+20,014
+8% +$449K 0.32% 53
2023
Q2 		$6.15M Sell
263,350
-44,150
-14% -$1.06M 0.41% 44
2023
Q1 		$7.16M Buy
307,500
+152,195
+98% +$3.81M 0.43% 43
2022
Q4 		$3.91M Sell
155,305
-150,600
-49% -$4.05M 0.23% 59
2022
Q3 		$8.07M Buy
305,905
+6,030
+2% +$186K 0.55% 36
2022
Q2 		$8.67M Buy
299,875
+75,305
+34% +$2.25M 0.57% 36
2022
Q1 		$7.74M Buy
224,570
+86,435
+63% +$3.05M 0.47% 37
2021
Q4 		$6.05M Sell
138,135
-22,860
-14% -$1.08M 0.37% 44
2021
Q3 		$8.16M Sell
160,995
-1,895
-1% -$98.8K 0.83% 18
2021
Q2 		$8.47M Buy
162,890
+44,155
+37% +$2.07M 0.66% 31
2021
Q1 		$5.43M Buy
118,735
+97,625
+462% +$4.77M 0.42% 38
2020
Q4 		$970K Sell
21,110
-195
-0.9% -$8.42K 0.08% 60
2020
Q3 		$830K Buy
21,305
+3,355
+19% +$129K 0.08% 58
2020
Q2 		$682K Buy
+17,950
New +$606K 0.07% 61

Other funds holding IDNA

UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
PGA
Portland Global Advisors Portland, Maine $1.05B AUM 18.22% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
TF
Trek Financial Scottsdale, Arizona $2.01B AUM 53.49% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return

Wharton Business Group's IDNA Position: Q2 2026 in Review

Wharton Business Group reduced its iShares Genomics Immunology and Healthcare ETF (IDNA) stake by 0.56% in Q2 2026, selling an estimated $45.4K and leaving 268,472 shares worth $9.06M. The position accounts for 0.3% of the portfolio, ranked #50.

Wharton Business Group first reported a position in IDNA in Q2 2020 and has held it in 25 quarters since. 65 funds tracked by Wall St. Rank hold IDNA as of Q2 2026.

  • Wharton Business Group held 268,472 shares of iShares Genomics Immunology and Healthcare ETF worth $9.06M as of Q2 2026.
  • Wharton Business Group sold 1,515 iShares Genomics Immunology and Healthcare ETF shares in Q2 2026, an estimated $45.4K.
  • iShares Genomics Immunology and Healthcare ETF made up 0.3% of Wharton Business Group's portfolio in Q2 2026, its #50 holding.
  • Wharton Business Group first reported a position in iShares Genomics Immunology and Healthcare ETF in Q2 2020 and has held it in 25 quarters since.
  • 65 funds tracked by Wall St. Rank held iShares Genomics Immunology and Healthcare ETF as of Q2 2026.

Based on Wharton Business Group's 13F filing for Q2 2026, filed 10 Aug 2026.